Miso Sabovic1, Simona Lavre, Irena Keber. 1. Department for Vascular Diseases, Internal Clinic, University Clinical Centre, Ljubljana, Slovenia. miso.sabovicx@trnovo.kclj.si
Abstract
OBJECTIVES: We explored the effects of regular consumption of wheat fibre in patients with dysmetabolic cardiovascular syndrome (MCVS). SUBJECTS AND METHODS: Forty-two patients with MCVS (mean age 49+/-8 years) were randomly assigned to a treated group (n=21) or to a control group (n=21). Patients in the treated group ate 10.5 g of wheat fibre powder per day for the first week, followed by 21 g per day for the next 4 weeks. A standard high-fibre diet was recommended to both groups. Blood pressure, metabolic parameters, fibrinolytic parameters and factor VII activity were measured at entry and after 5 and 9 weeks. RESULTS: After completing treatment, patients from both groups lost an average of 1 kg weight. Consumption of wheat fibre resulted in a significant (P<0.05) decrease of systolic and diastolic blood pressure, fasting glucose, glucose 2 h after oral glucose challenge (OGC), total cholesterol, low-density and high-density lipoprotein cholesterol, ranging from 7% to 18%. Furthermore, no significant reductions in fasting insulin, insulin 1 and 2 h after OGC, and glucose 1 h after OGC were found, whereas no differences in fibrinolytic parameters and factor VII activity were observed. Almost all beneficial effects of wheat fibre diminished 4 weeks after its withdrawal. In the non-treated group only a significant decrease of systolic pressure was observed. CONCLUSIONS: Our results suggest that supplementation of wheat fibre, not just a standard high-fibre diet, may improve cardiovascular risk profile in patients with MCVS, in a manner independent of weight reduction.
RCT Entities:
OBJECTIVES: We explored the effects of regular consumption of wheatfibre in patients with dysmetabolic cardiovascular syndrome (MCVS). SUBJECTS AND METHODS: Forty-two patients with MCVS (mean age 49+/-8 years) were randomly assigned to a treated group (n=21) or to a control group (n=21). Patients in the treated group ate 10.5 g of wheatfibre powder per day for the first week, followed by 21 g per day for the next 4 weeks. A standard high-fibre diet was recommended to both groups. Blood pressure, metabolic parameters, fibrinolytic parameters and factor VII activity were measured at entry and after 5 and 9 weeks. RESULTS: After completing treatment, patients from both groups lost an average of 1 kg weight. Consumption of wheatfibre resulted in a significant (P<0.05) decrease of systolic and diastolic blood pressure, fasting glucose, glucose 2 h after oral glucose challenge (OGC), total cholesterol, low-density and high-density lipoprotein cholesterol, ranging from 7% to 18%. Furthermore, no significant reductions in fasting insulin, insulin 1 and 2 h after OGC, and glucose 1 h after OGC were found, whereas no differences in fibrinolytic parameters and factor VII activity were observed. Almost all beneficial effects of wheatfibre diminished 4 weeks after its withdrawal. In the non-treated group only a significant decrease of systolic pressure was observed. CONCLUSIONS: Our results suggest that supplementation of wheatfibre, not just a standard high-fibre diet, may improve cardiovascular risk profile in patients with MCVS, in a manner independent of weight reduction.
Authors: Cheryl H Gilhooly; Sai Krupa Das; Julie K Golden; Megan A McCrory; James Rochon; James P DeLany; Alicia M Freed; Paul J Fuss; Gerard E Dallal; Edward Saltzman; Susan B Roberts Journal: Aging Clin Exp Res Date: 2008-12 Impact factor: 3.636